HEALTH● LOWAug 13 · Aug 13, 2026, 11:18 PM
Belite Bio outlines February 12, 2027 PDUFA date for Tinlarebant in Stargardt disease following FDA priority review acceptance
Seeking Alpha Tech
Belite Bio has received FDA priority review acceptance for Tinlarebant in Stargardt disease, with a PDUFA date set for February 12, 2027. This marks a key milestone in the drug's development and potential availability for patients.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH10m agoProud Kakinada is at the heart of India’s return to making Penicillin, says Andhra HRD Minister Nara LokeshThe HinduHEALTH13m agoKeralam to adopt calendar-based infectious disease prevention strategyThe HinduHEALTH24m agoItaly first in Europe to establish national plan against fentanyl says MeloniANSA [en]HEALTH28m agoMalaria: Nigeria’s prevalence drops to 15.2%, FG targets 50% reduction by 2030Vanguard Nigeria